Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Davita Inc (DVA) vs Kinross Gold Corporation (KGC) Price & Performance

Davita IncTrade
Kinross Gold CorporationTrade

Price performance (Past 24H)

Key statistics

Davita Inc vs Kinross Gold Corporation — how do they compare? Davita Inc trades at $178.17 (market cap $11.38B), while Kinross Gold Corporation trades at $27.59 (market cap $32.29B). The key difference: Kinross Gold Corporation is far larger — about 2.8× Davita Inc's market cap, and Kinross Gold Corporation pays a 0.59% dividend while Davita Inc pays none. Which is the better fit depends on your goals.

DVAKGC
Market Cap
$11.38B$32.29B
Sector
HealthBasic Materials
52-Week High
$240.96$38.06
52-Week Low
$103.87$18.70
Enterprise Value
$24.10B$30.37B
Dividend Yield
0.59%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Davita Inc

DaVita (DVA) trades at $183.69, down slightly by 0.04% over the past day. The stock shows strong fundamental performance with consistent earnings beats in recent quarters, including Q2 2026 EPS of $4.02 versus $3.88 expected (Zacks Investment Research, 2026-08-04). However, technical indicators signal a bearish trend, with the price near key support at $182. Revenue growth remains steady, climbing to $13.64 billion in 2025, though net income margin dipped to 5.47%.

The outlook is mixed; analyst consensus leans bullish with a $232.25 price target (MarketBeat, 2026-08-05), but risks include reimbursement pressure and high debt levels. Investment appeal hinges on execution against guidance amid payer-mix challenges, with the current valuation offering potential upside if operational trends stabilize.

Kinross Gold Corporation

KGC trades at $27.40, down 0.87% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported strong Q2 2026 earnings of $0.71 per share, beating estimates, and maintains robust fundamentals with a P/E of 10.36 and net income margin of 37.52%. Recent news includes an S&P credit upgrade to 'BBB' and progress on the Lobo-Marte project, signaling operational strength.

The outlook is positive, driven by earnings beats, rising free cash flow, and a consensus price target of $37.20 offering ~36% upside. Risks include cost pressures, gold price volatility, and execution of growth projects. Analyst sentiment is bullish with 59% buy ratings, but investors should monitor Q3 2026 results for sustained momentum.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Davita Inc

DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.

Read more on DVA

About Kinross Gold Corporation

Kinross Gold is a Canada-based senior gold producer, producing roughly 2.4 million gold equivalent ounces in 2020. The company had 30 million ounces of proven and probable gold reserves and 59 million ounces of silver reserves at the end of 2020. It operates mines and focuses its greenfield and brownfield exploration in the Americas, West Africa, and Russia. The company has historically used acquisitions to fuel expansion into new regions and production growth.

Read more on KGC